MedTrace Logo

Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction

NCT02808273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2019-02-11

No results posted yet for this study

Summary

A comparative study to reveal if the use of Bemiparine (Hibor) versus Enoxaparin (Clexane) as an antithrombotic agent, shows an advantage on the rate of thrombotic and haemorrhagic events in microsurgicals free flaps during head and neck reconstruction.

Conditions

  • Patients Undergoing Microvascular Surgery

Interventions

DRUG

Bemiparine

Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis

Sponsors & Collaborators

  • Rovi Pharmaceuticals Laboratories

    collaborator INDUSTRY

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

    lead OTHER

Principal Investigators

  • Julio Acero Sanz, MD; PhD · Ramon y Cajal Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-02
Primary Completion
2018-10-12
Completion
2018-10-12

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808273 on ClinicalTrials.gov